

HEADACHE Toolbox

Injection Procedure Record for OnabotulinumtoxinA (BOTOX[®], Allergan, Inc., Irvine, CA, USA) Treatment

Patient Name:		Date:	
Headache Diagnosis, History, and Symptoms:			
Frequency of Headache days per month: _____		Frequency of Migraine days per month: _____	
MIDAS Score (0 to 21+) _____	Grade I (0-5)	Grade II (6-10)	Grade III (11-20) Grade IV (21+)
HIT-6 Score (range: 36 to 78) _____	Grade I (36-49)	Grade II (50-55)	Grade III (56-59) Grade IV (60-78)
Predominant, usual pain location and/or muscle tenderness upon palpation (check all that are applicable):			
	Temporalis	Occipitalis	Trapezius
Left side	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Right side	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Previous onabotulinumtoxinA injections for chronic migraine: (recommended retreatment is every 12 weeks)		Yes <input type="checkbox"/> Date: _____	No <input type="checkbox"/>
Review injection procedure, risks, and benefits with patient*			
Dilution: 100 U BOTOX diluted in 2 mL preservative-free 0.9% saline			
Inject 0.1 mL (5 U) to each injection site using a 30-gauge, half-inch needle			
Injection Sites: No. of Units (U) per Muscle (No. of Injection Sites)			
	Fixed Site, Fixed Dose	Check When Completed	Follow-the-Pain (Optional)
Head/Neck Area			Left Right
Corrugator ⁺	10 U (divided in 2 sites)	<input type="checkbox"/>	
Procerus ⁺	5 U (in 1 site)	<input type="checkbox"/>	
Frontalis ⁺	20 U (divided in 4 sites)	<input type="checkbox"/>	
Temporalis ⁺	40 U (divided in 8 sites)	<input type="checkbox"/>	≤10 U (≤2 sites) ___U ___U
Occipitalis ⁺	30 U (divided in 6 sites)	<input type="checkbox"/>	≤10 U (≤2 sites) ___U ___U
Cervical paraspinal ⁺	20 U (divided in 4 sites)	<input type="checkbox"/>	
Trapezius ⁺	30 U (divided in 6 sites)	<input type="checkbox"/>	≤20 U (≤4 sites) ___U ___U
Total	155 U		___U ___U
Injector Signature and Date:			

Andrew M. Blumenfeld, MD
 Director, The Headache Center of Southern California, Encinitas, CA, USA

*Reminder: If required per standard operating procedures for clinic/institution, obtain informed consent from the patient for this treatment. [†]Dose distributed bilaterally.